SCHEMBL24809013

SCHEMBL24809013

CS(=O)(=O)CC1CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.46
CYP3A4 P08684 4/20 0.46
ALOX15 P16050 1/20 0.44
TSHR P16473 2/20 0.44
CYP2C19 P33261 2/20 0.44
MAPK1 P28482 2/20 0.44
USP2 O75604 1/20 0.44
CYP2C9 P11712 1/20 0.44
SLC6A9 P48067 1/20 0.43
CYP1A2 P05177 1/20 0.43
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
ADRA2A P08913 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
DRD1 P21728 1/20 0.42
ADRA1D P25100 1/20 0.42
HTR2A P28223 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL85392 0.84 OPRM1 (0.48) CYP2D6SLC6A9CHRM2CHRM4CHRM5
SCHEMBL1130577 0.84 SLC6A9 (0.43) MAPK1SLC6A9OPRM1SCN9ASCN7A
SCHEMBL1122107 0.80 SCN9A (0.47) CYP2D6CYP3A4ALOX15TSHRCYP2C19
SCHEMBL16759363 0.79 SLC6A9 (0.46) CYP2D6SLC6A9CHRM2CHRM4CHRM5
SCHEMBL2031016 0.78 CYP2D6 (0.49) CYP2D6CYP3A4ALOX15TSHRCYP2C19
SCHEMBL8573441 0.78 LMNA (0.48) CYP2D6CHRM2CHRM4CHRM1OPRM1
SCHEMBL1121906 0.78 KMT2A (0.43) MAPK1OPRM1SCN9ASCN7ASCN5A
SCHEMBL1121697 0.77 SCN9A (0.40) MAPK1SLC6A9OPRM1SCN9ASCN7A
SCHEMBL27262604 0.76 DPP4 (0.38) CYP2D6CYP3A4ALOX15TSHRCYP2C19
SCHEMBL5745379 0.75 CYP2D6 (0.47) CYP2D6CYP3A4ALOX15TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022271613-A1 HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER BLUEPRINT MEDICINES CORPORATION (US) 2022-12-29 WO disclosed
CN-1278530-A Novel peptide derivative ASTRA AB (SE) 2001-01-03 CN disclosed